Twenty-four-hour intragastric pH: Tolerance within 5 days of continuous ranitidine administration

American Journal of Gastroenterology

Volumn 95, Issue 1, 2000, Pages 57-61

  Lachman, Leonard ^a   Howden, Colin W ^b  

^a Phoenix Intl (Formerly IBRD Ctr C   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANITIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERANCE; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH PH;

ADMINISTRATION, ORAL; ADULT; ANTI-ULCER AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; MONITORING, AMBULATORY; RANITIDINE;

EID: 0033987730     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(99)00760-1     Document Type: Article

References (23)

1. Wilder-Smith C., Halter F., Ernst T., et al. Loss of acid suppression during dosing with H2-receptor antagonists. Aliment Pharmacol Ther. 4:(suppl 1):1990;15-27.
2. Smith J.T.L., Gavey C., Nwokolo C.U., et al. Tolerance during 8 days of high-dose H2-blockade Placebo-controlled studies of 24-hour acidity and gastrin . Aliment Pharmacol Ther. 4:(suppl 1):1990;47-63.
3. Nwokolo C.U., Smith J.T.L., Gavey C., et al. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine, or ranitidine. Aliment Pharmacol Ther. 4:(suppl 1):1990;29-45.
4. 2-receptor antagonists. Dig Dis Sci. 35:1990;976-983.
5. Nwokolo C.U., Prewett E.J., Sawyerr A.F.M., et al. Tolerance during 5 months of dosing with ranitidine, 150 mg nightly A placebo-controlled, double-blind study . Gastroenterol. 101:1991;948-953.
6. Wilder-Smith C.H., Merki H.S. Tolerance during dosing with H2-receptor antagonists. An overview. Scand J Gastroenterol. 27:(suppl 193):1992;14-19.
7. Sandvik A.K., Brenna E., Waldum H.L. The pharmacological inhibition of gastric acid secretion-tolerance and rebound. Aliment Pharmacol Ther. 11:1997;1013-1018.
8. Netzer P., Gaia C., Sandoz M., et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol. 94:1999;351-357.
9. Grossman M.I., Konturek S.J. Inhibition of acid secretion in the dog by metiamide, a histamine antagonist acting on H2 receptors. Gastroenterol. 66:1974;517-521.
10. Takeuchi K., Speir G.R., Johnson L.R. Mucosal gastrin receptor. III Regulation by gastrin. Am J Physiol. 238:1980;G135-G140.
11. Johnson L.R., Aures D., Hakanson R. Effect of gastrin on the in vivo incorporation of C14-leucine into protein of the digestive tract. Proc Soc Exp Biol Med. 132:1969;996-998.
12. 2-receptor antagonist. Gut. 29:1988;890-893.
13. Nwokolo C.U., Smith J.T.L., Sawyerr A.M., et al. Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2-receptor blockade. Gut. 32:1991;1455-1460.
14. Bell N.J.V., Chiba N., Ringham G.L., et al. Time to maximum effect of lansoprazole on gastric pH in male, normal volunteers. Gastroenterol. 101:1992;A345. (abstract).
15. Atanassoff P.G., Brull S.J., Weiss B.M., et al. The time course of gastric pH changes induced by omeprazole and ranitidine A 24-hour dose-response study . Anesth Analg. 80:1995;975-979.
16. Houben G.M., Hooi J., Hameeteman W., et al. Twenty-four hour intragastric acidity 300 mg Ranitidine b.d., 20 mg omeprazole o.m., 40 mg omeprazole o.m. vs. placebo . Aliment Pharmacol Ther. 9:1995;649-654.
17. Blum R.A., Shi H., Karol M., et al. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther. 19:1997;1013-1023.
18. Meyer M., Meier J., Drewe J. Effect of lansoprazole and ranitidine on gastric acidity in healthy volunteers. Gastroenterol. 112:1997;A219. (abstract).
19. Reill L., Erhardt F., Fishcher R., et al. Intragastric pH and serum gastrin after one treatment with pantoprazole, ranitidine, or placebo in man. Gastroenterol. 104:1993;A177. (abstract).
20. Chiba N., de Gara C.J., Wilkinson J.M., et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease A meta-analysis . Gastroenterol. 112:1997;1798-1810.
21. 2RAs). Gastroenterol. 114:1998;A154. (abstract).
22. Vigneri S., Termini R., Leandro G., et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 333:1995;1106-1110.
23. Gough A.L., Long R.G., Cooper B.T., et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther. 10:1996;529-539.